Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otamixaban versus unfractionated heparin + eptifibatide in non-ST-segment elevation acute coronary syndrome undergoing early invasive management
2009-016568-36Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of otamixaban in acute coronary syndrome (ACS), unstable angina and Myocardial Infarction (MI) (2 arms), sponsored by Sanofi. Primary endpoints: Primary endpoint sensitivity analysis and Key efficacy objective 1. Started Feb 2010; status: completed.
02
Drugs
otamixaban
03
Conditions
acute coronary syndrome (ACS)unstable anginaMyocardial Infarction (MI)
Beyond the preview
Go deeper on 2009-016568-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016568-36.